Skip to content
Triangle logo TriangleGet started
← Full study record

NCT03912064 · OUTCOME

Maximum Tolerated Dose (MTD) for Ipilimumab

A Phase 1 Trial of CD25/Treg-depleted DLI Plus Ipilimumab for Myeloid Disease Relapse After Matched-HCT · Source last updated 2026-01-05

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
mg/kg
Interval / dispersion
Not reported
Time frame
Day 43 (6 weeks)

What was measured

The primary objective of this study is to determine the safety (MTD) of CD25/Treg-depleted donor lymphocyte infusion (DLI) plus Ipilimumab in patients with myeloid relapse after matched-HCT. Participants will be evaluated for dose limiting toxicities (DLTs) at day 43. DLTs explained within section 5.4 of the protocol.

Groups in this outcome

Ipilimumab

Ipilimumab: Ipilimumab is an antibody that acts against CTLA-4 -Ipilimumab is administered intravenously every 12 weeks CD25hi Treg depleted DLI: Donor lymphocyte product -Patients will receive a defined dose of CD25hi Treg depleted DLI intravenously

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Ipilimumab25

Reported measurements

Source class 1
Values in mg/kg · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Ipilimumab1Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        1
denoms
  1. counts
    1. group Id
      OG000
      value
      25
    units
    Participants
description
The primary objective of this study is to determine the safety (MTD) of CD25/Treg-depleted donor lymphocyte infusion (DLI) plus Ipilimumab in patients with myeloid relapse after matched-HCT. Participants will be evaluated for dose limiting toxicities (DLTs) at day 43. DLTs explained within section 5.4 of the protocol.
groups
  1. description
    Ipilimumab: Ipilimumab is an antibody that acts against CTLA-4 -Ipilimumab is administered intravenously every 12 weeks CD25hi Treg depleted DLI: Donor lymphocyte product -Patients will receive a defined dose of CD25hi Treg depleted DLI intravenously
    id
    OG000
    title
    Ipilimumab
param Type
NUMBER
reporting Status
POSTED
time Frame
Day 43 (6 weeks)
title
Maximum Tolerated Dose (MTD) for Ipilimumab
type
PRIMARY
unit Of Measure
mg/kg

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice